By analyzing data from three clinical trials treating children with the brain tumor medulloblastoma, scientists at St. Jude Children’s Research Hospital have designed an approach to safely reduce therapy, thereby lowering side effects. The analysis of almost 900 patients included genomic, molecular and survival information, which was used to create new treatment risk groups. Physicians and scientists can explore these findings in an easy-to-use web-based portal specifically designed for analyzing medulloblastoma data. The findings and portal platform were published recently in Neuro-Oncology and Cancer Research, respectively.
This article was originally published on MedicalXpress.com
